Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126264291 | 12626429 | 1 | I | 20160726 | 20160805 | 20160805 | EXP | US-ELI_LILLY_AND_COMPANY-US201608002600 | ELI LILLY AND CO | 0.00 | A | Y | 0.00000 | 20160805 | MD | US | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126264291 | 12626429 | 1 | PS | GEMCITABINE HYDROCHLORIDE. | GEMCITABINE HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | 1000 MG/M2, CYCLICAL (ON DAYS 1 AND 8 OF EACH 21 DAY CYCLE) | U | U | 20509 | 1000 | MG/M**2 | ||||||
126264291 | 12626429 | 2 | SS | CISPLATIN. | CISPLATIN | 1 | Intravenous (not otherwise specified) | 70 MG/M2, CYCLICAL (DAY 1 OF EACH 21 DAY CYCLE) | U | U | 0 | 70 | MG/M**2 | ||||||
126264291 | 12626429 | 3 | SS | TYKERB | LAPATINIB DITOSYLATE | 1 | Oral | UNK UNK, QD | U | U | 0 | QD |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
126264291 | 12626429 | 1 | Bladder cancer |
126264291 | 12626429 | 2 | Bladder cancer |
126264291 | 12626429 | 3 | Bladder cancer |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
126264291 | 12626429 | HO |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
126264291 | 12626429 | Dehydration | |
126264291 | 12626429 | Diarrhoea |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
no results found |